to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Kaohsiung Medical University

Status: Invitation-only

Conditions: HELICOBACTER PYLORI INFECTIONS

Treatments: Drug: Bismuth amoxilillin potassium

Study type: Interventional

Funder types: Other

Identifiers

NCT07142798

KMUHIRB-F(I)-20240204

Details and patient eligibility

About

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subjects infected with Helicobacter pylori.

Exclusion criteria

1. Those who are allergic to the drugs used in this research.
2. Those who have had stomach surgery.
3. Those with severe liver cirrhosis or uremia or malignant tumors.
4. Women who are pregnant or breastfeeding. If you have drug allergies or pregnant women or breast-feeding women during the test period, you can withdraw from the test early.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

Helicbpacyer pylori infection

Experimental group

Description:

Helicbpacyer pylori infection

Treatment:

Drug: Bismuth amoxilillin potassium